Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 6 Neoplasms 3 Neoplasm Metastasis 3 Neuroendocrine Tumors 2 Neuroectodermal Tumors, Primitive 2 Glioblastoma 2 Carcinoma, Renal Cell 2 Uterine Neoplasms 1 Tuberous Sclerosis 1 Triple Negative Breast Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Perivascular Epithelioid Cell Neoplasms 1 Pancreatic Neoplasms 1 Malignant Solid Tumour 1 Leukemia, Myeloid, Acute 1 Kidney Neoplasms 1 Hamartoma Syndrome, Multiple 1 Gliosarcoma 1 Endometrial Neoplasms 1 Castration-resistant Prostate Cancer 1 Castrate-resistant Prostate Cancer 1 Carcinoma, Transitional Cell 1 Breast Diseases 1 Brain Neoplasms 1 Angiomyolipoma 1 Advanced Solid Tumor 1

Interventions

pembrolizumab 91 Gemcitabine 56 Nivolumab 50 Cisplatin 39 atezolizumab 37 Carboplatin 30 avelumab 29 enfortumab vedotin 25 Docetaxel 23 Magnetic Resonance Spectroscopy 19 Mitomycin 17 Ipilimumab 17 Paclitaxel 16 Specimen Handling 14 durvalumab 11 toripalimab 10 sacituzumab govitecan 10 Pemetrexed 10 cabozantinib 9 Taxes 8 vinflunine 7 Cyclophosphamide 7 tislelizumab 6 Injections 6 Bevacizumab 6 pemigatinib 5 fludarabine 5 disitamab vedotin 5 Standard of Care 5 Radiosurgery 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × dactolisib × Clear all

NCT01856101 2019-04-10

BEZ235

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 2 Terminated

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡